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INTRODUCTION: THE DENGUE VACCINE 
CONTROVERSY
In 2016, the Philippines embarked on an 
unprecedented mass immunisation campaign 
against dengue fever, becoming the first Asian 
nation to authorise the commercial use of 
Dengvaxia, the dengue vaccine manufactured 
by the French pharmaceutical Sanofi Pasteur.1 
In December 2017, nearly 2 years since the 
campaign started, Sanofi announced that 
Dengvaxia may actually cause ‘more severe 
disease’ in those who have not had previous 
dengue infection.2 By then, over 800,000 Fili-
pino schoolchildren had been inoculated.1
Criminal investigations against involved 
government figures ensued, with one critic 
likening the mass vaccination programme to 
a ‘genocide against Filipino children’.3 The 
deaths of several children who had received 
the vaccine became a focal point of the 
scandal, as the Public Attorney’s Office ran 
a highly publicised and dramatised investi-
gation, from televised autopsies to the chief 
lawyer appearing alongside the grieving 
mothers in media interviews.3–5 The resulting 
‘crisis of confidence’ against the public health 
sector sent immunisation rates plummeting 
to an all- time low, precipitating a measles 
outbreak across the country, exacerbating 
already- low immunisation rates.5
What went wrong, and how could a 
different—or more deliberate—communi-
cations strategy have contributed to averting 
those mistakes? In this article, we identify 
several lessons on health communication 
from the dengue vaccine controversy that 
may prove beneficial in light of the COVID-19 
pandemic, given the emergent parallels 
between the two health crises.
TRUST AND CREDIBILITY
Fundamentally, effective health communica-
tion entails trust between the public and the 
scientific community. Building confidence 
in vaccines ‘implies trust in the vaccine (the 
product), trust in the vaccinator or other 
health professional (the provider), and 
trust in those who make the decisions about 
vaccine provision (the policy- maker)’.6 In 
other words, trust springs from credibility.
One way to do this is through deference 
to non- partisan, expert institutions and 
upholding the credibility of these institu-
tions. In the dengue vaccine controversy, this 
was seen in the involvement of the Philippine 
General Hospital’s independent panel of 
experts who became the de facto unbiased 
inquisitors of the sensationalised turn of 
events. Unfortunately, though their investiga-
tion virtually exonerated the vaccine from the 
deaths of the children, these experts had to 
compete with many other voices, mostly from 
government, that only undermined whatever 
authority they may have held during the crisis.
Under COVID-19, the importance of 
letting scientific institutions take the lead 
in communications cannot be overstated. 
These institutions remain our most credible 
sources of information; thus, they must lead 
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 ► As countries around the world begin to roll out 
COVID-19 vaccines, vaccine safety communication 
is more relevant than ever.
 ► The dengue vaccine controversy in the Philippines 
offers lessons that can be applied to immunisation 
programmes being organised today to address the 
COVID-19 pandemic.
 ► Effective vaccine safety communication entails (re)
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and the public, upholding the credibility of scientific 
institutions and maintaining transparency.
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framework of equity, using an interdisciplinary ap-
proach to health communication and putting a pre-
mium on public feedback.
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without interference—or perceived interference—from 
partisan figures. Politicians may help inspire public confi-
dence towards vaccination, but too often they engage in 
medical populist tropes, such as passing off unfounded 
knowledge claims as facts, that are damaging to the 
scientific institutions.3 4 Left unchecked, these political 
tactics result in ‘vaccine messianism’, where politicians 
overemphasise their faith in vaccines, obscuring what the 
scientific community has actually proven thus far,7 And 
a public that views vaccines as mere political tools being 
wielded by actors in power, as what transpired during the 
dengue vaccine controversy, will only end up rejecting a 
vaccine, no matter how efficacious.
TRANSPARENCY
Related to trust and credibility is transparency, which 
entails a consistent effort to disclose necessary informa-
tion from all parties in any health- related endeavour. 
This means not just being upfront about factual informa-
tion—the science of newly manufactured vaccines, their 
risks and limitations—but also about the circumstances 
with which they will be given to an anxious public.
The late disclosure of the dengue vaccine’s poten-
tially life- threatening effects led to accusations of lack 
of transparency and widespread speculation that the 
programme, with its multibillion- peso funding, was in 
reality railroaded by corrupt practices.8 Separately, under 
COVID-19, violations of this cardinal rule of transparency 
have already transpired in the Philippines even before 
public vaccinations have started: in December 2020, it 
was discovered that no less than members of the Presi-
dential Security Group had been injected with the yet- to- 
be- approved Sinopharm vaccines, smuggled from China; 
worse, a black market of illegal vaccinations among 
Chinese nationals in the country was apparently being 
tolerated by the government.9 10 These situations, instead 
of pre- empting feelings of suspicion towards vaccines, 
only worsen the public’s mistrust towards their govern-
ment and, consequently, towards vaccines themselves.
EQUITY
Another important tenet is equity—the vulnerable and 
marginalised on equal footing with the privileged. In 
the dengue vaccine controversy, a point of inequity was 
initially raised by politicians who questioned the selec-
tion process for the programme’s implementation; why, 
during an election year, certain administrative regions 
were supposedly ‘prioritised’ over others.11 Subsequently, 
inequity could be seen in the way local government 
units—some more resource- rich than others—were 
forced to intervene in the aftermath of the national 
communication breakdown.
A year into the COVID-19 pandemic, equity red flags 
have been raised again and again—from politicians 
flouting quarantine measures, to these same politicians 
abusing their authority and disregarding the ‘prioritisa-
tion list’ of the vaccination process.12 At the same time, 
news of numerous highly urbanised cities forging their 
own vaccination deals with international pharmaceuti-
cals have raised fears that such undertakings will result 
to geographic inequity, with poorer cities and regions 
at a disadvantage.13 Equity in vaccine communication 
therefore entails looking at vaccination against the 
broader public health infrastructure, with clear guide-
lines, audience segmentation and targeted campaigns 
emphasising—and insisting on—universal access to the 
vaccines. This will not only streamline COVID-19 vaccina-
tions, but in the long run, even improve coverage rates of 
existing vaccines.
PARTICIPATION AND FEEDBACK
Finally, effective health communication means 
accounting for participation and feedback. As shown by 
the dengue vaccine controversy, ‘expertise’ is not enough 
in the face of insufficient ‘buy- in’ from all concerned 
sectors, including within the scientific community.
Participation means recognising that vaccine hesi-
tancy—and vaccine safety communication—involves 
not just the scientific community but every other institu-
tion across political and civil society. Against a predom-
inantly Western framework of science communication, 
it will entail synchronous, interdisciplinary engagement 
among: primary care workers who know the situation 
on the ground (ie, hospital and community settings); 
social science and communications experts with the 
necessary tools to understand ‘local vaccine culture’—
the root of people’s fears, distrust and (mis)conceptions 
regarding vaccines, as well as the healthcare system14–16; 
media workers who must ensure that the information 
being relayed to the public do not get sensationalised or 
distorted; and even religious and civil society groups with 
established influence over their communities. Addition-
ally, this will also entail ‘starting young’—integrating and 
emphasising the importance of healthcare communica-
tions into the training curricula of hospitals and medical 
schools.17
Most importantly, participatory communication 
means putting a premium on feedback, showing people 
that their government is responding to them. With the 
dengue vaccine controversy, the failure of government to 
preserve feedback mechanisms led to the rise of ‘moral 
entrepreneurs’ who manufactured competing narratives 
and overwhelmed communication channels, both in 
mass and social media.4
However, feedback can also be a means for authorities 
to know what the people are thinking—and thinking 
incorrectly. Under COVID-19, a vigorous feedback mech-
anism can pre- empt misinformation and disinformation, 
especially online.18 19 This means not just anticipating 
occasions of fake news but also occasions to be honest to 
the public regarding vaccine risks and failure. Not only 
for vaccine communication, but health communications 
in general, investing in improving feedback mechanisms 
has become an essential—and life- saving—path forward.
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CONCLUSION
Vaccine mistrust is not irreversible; a study comparing 
vaccine confidence before and after the dengue vaccine 
was administered in the Philippines showed that while 
confidence levels had indeed plunged, they had also seen 
a relative, gradual increase, suggesting that attitudes can 
be swayed over time.20
However, as the Philippine experience hopefully makes 
clear, especially for countries in similar straits, rebuilding 
trust in vaccines, and the healthcare system, is an arduous 
road forward, where partnerships between the authori-
ties and the public must be re- established through trans-
parent systems, on top of long- term investments towards 
the healthcare infrastructure. Politicisation must be 
avoided at all costs, and credible, non- partisan actors 
must be at the forefront of communicating the case 
for immunisation. Checks and balances must always be 
preserved, which means both the public—including the 
medical community—fulfilling its role as active, critical 
participants of the healthcare system and the govern-
ment being accountable at all times for all its actions—
and inactions. Absent such deliberate efforts, any vaccine 
produced to stomp the pandemic will only go to waste.
Twitter Gideon Lasco @gideonlasco
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